Rani Therapeutics
Présence
Rani Therapeutics est une société cotée sous le symbole boursier RANI (US).
Dirigeants
Voir l'organigramme avec ses 18 principaux dirigeants
Biographies les plus recherchées chez Rani Therapeutics
- Talat Imran, Chief Executive Officer
- Andrew Farquharson, Director
- Mir Imran, Executive Chairman of the Board
Créer une alerte
pour suivre les mouvements de dirigeants chez Rani Therapeutics.
Biotechnologie
Rani Therapeutics a 2 285 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Karius vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 3 mai 2024).
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Rani Therapeutics
- Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - Rani Therapeutics, LLC
- Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - Rani Therapeutics, LLC
- Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - Rani Therapeutics, LLC
- Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
- Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Qu
- The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Rani Therapeutics, LLC
- Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study - Rani Therapeutics, LLC
- Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research - Rani Therapeutics, LLC
- Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) - Rani Therapeutics, LLC
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Rani Therapeutics
- Rani Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Rani Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Talat Imran 
Appelez Rani Therapeutics au +1 408...
